Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrated proteogenomic and metabolomic profiling of acute myeloid leukemias to identify molecular subtypes and associated therapy targets.

Nature cancer·2026
Same author

Navigating luminal heterogeneity: etiology-based proteogenomic subtyping for targeted treatment strategies in breast cancer.

Molecular cancer·2026
Same author

Artificial intelligence in cancer diagnostics: a primer for clinicians and scientists.

Journal of the National Cancer Institute·2026
Same author

A 15-layer multi-omics analysis of gastric cancer ecotypes provides therapeutic insights.

Cell reports. Medicine·2026
Same author

Pharmacologic activation of Δ133p53α reduces cellular senescence in progeria patients-derived cells.

Aging pathobiology and therapeutics·2025
Same author

Pharmacologic activation of Δ133p53α reduces cellular senescence in progeria patients-derived cells.

bioRxiv : the preprint server for biology·2025
Same journal

Adjuvant epidermal growth factor receptor tyrosine kinase inhibitor in resected stage N2 non-small cell lung cancer harboring <i>EGFR</i> mutation.

Translational lung cancer research·2026
Same journal

Annual progress in transbronchial diagnosis and treatment of pulmonary malignant tumors [2025]: a narrative review.

Translational lung cancer research·2026
Same journal

Prognostic value of ROS1 rearrangement in lung adenocarcinoma stratified by clinicopathologic and radiological features: a retrospective cohort study.

Translational lung cancer research·2026
Same journal

Case report: first-line lorlatinib in metastatic lung adenocarcinoma with a novel WIPF1-ALK and EML4-ALK dual fusion.

Translational lung cancer research·2026
Same journal

Challenges for first-line therapy in elderly patients with metastatic non-small cell lung cancer.

Translational lung cancer research·2026
Same journal

Macrophages in lung cancer: principal factors, regulatory mechanisms, and therapeutic opportunities: a narrative review.

Translational lung cancer research·2026
See all related articles

Related Experiment Video

Updated: Mar 12, 2026

Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients
13:21

Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients

Published on: June 16, 2017

10.6K

Methylation analyses in liquid biopsy.

Delphine Lissa1, Ana I Robles1

  • 1Laboratory of Human Carcinogenesis, National Cancer Institute, NIH, Bethesda, MD 20892, USA.

Translational Lung Cancer Research
|November 10, 2016
PubMed
Summary
This summary is machine-generated.

Methylated circulating tumor DNA (ctDNA) shows promise as a noninvasive biomarker for early lung cancer detection, prognosis, and monitoring treatment response. Further research is needed to integrate methylated ctDNA into routine clinical practice.

Keywords:
Circulating tumor DNA (ctDNA)biomarkerbisulfite-based PCR assayscancer monitoringearly detectionprognosis

More Related Videos

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer
07:50

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer

Published on: September 18, 2020

6.2K
LINE-1 Methylation Analysis in Mesenchymal Stem Cells Treated with Osteosarcoma-Derived Extracellular Vesicles
12:18

LINE-1 Methylation Analysis in Mesenchymal Stem Cells Treated with Osteosarcoma-Derived Extracellular Vesicles

Published on: February 1, 2020

6.2K

Related Experiment Videos

Last Updated: Mar 12, 2026

Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients
13:21

Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients

Published on: June 16, 2017

10.6K
Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer
07:50

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer

Published on: September 18, 2020

6.2K
LINE-1 Methylation Analysis in Mesenchymal Stem Cells Treated with Osteosarcoma-Derived Extracellular Vesicles
12:18

LINE-1 Methylation Analysis in Mesenchymal Stem Cells Treated with Osteosarcoma-Derived Extracellular Vesicles

Published on: February 1, 2020

6.2K

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Lung cancer remains a leading cause of cancer mortality globally.
  • Low-dose computed tomography (LDCT) screening aids early diagnosis but requires improved biomarkers for eligibility and accuracy.
  • Biomarkers are crucial for prognostic stratification and monitoring tumor evolution in early-stage lung cancer.

Approach:

  • This review explores the investigational applications of methylated circulating tumor DNA (ctDNA) in lung cancer.
  • It summarizes technologies for DNA methylation analysis in liquid biopsies.
  • Challenges for clinical implementation of methylated ctDNA are also discussed.

Key Points:

  • Circulating tumor DNA (ctDNA), including its methylated forms, offers a noninvasive alternative to tissue biopsies.
  • Activating gene mutations in ctDNA predict targeted therapy response and aid longitudinal monitoring.
  • DNA methylation in ctDNA shows potential for early detection, prognosis, and real-time tumor dynamics tracking.

Conclusions:

  • Methylated ctDNA presents a promising avenue for advancing lung cancer diagnostics and management.
  • Technological advancements in liquid biopsy analysis are key to realizing its clinical potential.
  • Overcoming implementation challenges is essential for integrating methylated ctDNA into routine clinical practice.